RCUS - Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company’s financial results for the quarter and year ended December 31 st , 2023.
Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 235272. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com . A replay of the webcast will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207640939/en/
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Investor Inquiries
Pia Eaves
Head of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com